Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Safety, Tolerability, and Pharmacokinetic Study of Single and Multiple Ascending Dose of YY524051 Tablets in Healthy Adults.

13. november 2026 oppdatert av: Beijing Baheal Wisart Medical Research Co., Ltd

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral YY524051 Tablets in Healthy Participants

This is a Phase 1 study to evaluate the safety, tolerability, and how the body processes an investigational drug called YY524051 tablets in healthy participants.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Detaljert beskrivelse

This is a single-center Phase 1, randomized, double-blind, placebo controlled, first-in-human (FIH) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of an investigational drug called YY524051 tablets in healthy adult participants.

The study is divided into two parts:

Single Ascending Dose (SAD) part: Participants will receive a single dose of the drug to see how the body handles it and to determine a safe dose level. A staggered dosing schedule will be used, where a few "sentinel" participants will be dosed first to ensure safety before the rest of the cohort receives the drug. A food-effect (FE) assessment will be nested at a selected dose level after fasting dosing during escalation, and a clinical QT/QTc (CQTc) assessment will be embedded within selected SAD cohorts.

Multiple Ascending Dose (MAD) part: Participants will take the drug repeatedly over several days to assess accumulation and steady-state in the body and to further evaluate its safety.

Participants will be randomly assigned to receive either YY524051 tablets or a placebo (placebo tablet containing no active ingredient). The study is "double-blind," meaning neither the participants nor investigators will know who is receiving the real drug.

The information gathered from this study will help researchers understand the best way to give this drug, characterize its PK profile, and determine a safe dose for future studies in patients.

Studietype

Intervensjonell

Registrering (Antatt)

78

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Beijing, Kina
        • Peking University Third Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 45 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

Participants must meet ALL of the following criteria to be eligible for enrollment:

  • Healthy participants, male or female (the ratio of males to females will be kept as balanced as possible).
  • Age between 18 and 45 years (inclusive). Body weight ≥ 50 kg for males and ≥ 45 kg for females. Body Mass Index (BMI) between 19.0 and 28.0 kg/m² (inclusive). BMI = weight (kg) / height² (m²).
  • Able to understand the informed consent form, and voluntarily participate and sign the informed consent form.

Exclusion Criteria:

Participants who meet ANY of the following criteria will be excluded from the study:

  • History of drug allergy, or known allergy to the investigational product or any of its excipients (microcrystalline cellulose, mannitol, croscarmellose sodium, povidone, magnesium stearate, film coating premix (gastric-soluble), sodium stearyl fumarate, lactose);
  • History of or current clinically significant diseases in the circulatory, endocrine, nervous, digestive, respiratory, hematological, immunological, psychiatric, or metabolic systems, as determined by the investigator;
  • History of drug addiction; history of alcohol abuse within 6 months prior to screening (defined as consuming more than 14 standard units of alcohol per week [1 unit = 360 mL of beer, 45 mL of 40% spirits, or 150 mL of wine]); average daily cigarette consumption ≥ 5 cigarettes within 3 months prior to screening; positive urine drug screen or positive alcohol breath test at screening; or inability to comply with the prohibition of smoking/alcohol during the study period;
  • History of cardiovascular or cerebrovascular surgery; history of any surgery affecting drug absorption, distribution, metabolism, or excretion; severe trauma or surgery within 6 months prior to screening; or planned surgery during the study period;
  • Positive results for any of the following: Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibody (HCVAb), Treponema pallidum particle agglutination (TPPA), or Human Immunodeficiency Virus (HIV) antibody;
  • Positive pregnancy test for female participants;
  • Breastfeeding female participants; female participants who refuse to use effective non-pharmacological contraceptive measures (e.g., abstinence, intrauterine device) or have egg donation plans from signing the informed consent until 90 days after the last dose; male participants who refuse to commit to no reproductive or sperm donation plans or refuse to use effective physical contraceptive measures, or have sperm donation plans from signing the informed consent until 90 days after the last dose;
  • Abnormalities in physical examination, laboratory tests, vital signs, echocardiography, abdominal ultrasound, or chest X-ray that are clinically significant as determined by the investigator and may affect the evaluation of study endpoints;
  • Blood pressure ≥ 140/90 mmHg or < 90/50 mmHg; heart rate < 50 beats/min or > 100 beats/min;
  • Clinically significant abnormalities on 12-lead electrocardiogram (ECG) as determined by the investigator, including: Prolonged QT interval: QTcF > 450 msec (males) or > 470 msec (females); PR interval > 200 msec; QRS interval > 120 msec;
  • Consumption of excessive tea, coffee, or caffeine-containing beverages (≥ 8 cups per day, 1 cup = 250 mL) daily within 3 months prior to screening; or habitual consumption of any xanthine-rich beverages or foods (e.g., caffeine, theophylline, theobromine) or fruits/foods affecting metabolic enzymes (e.g., grapefruit, pomelo, starfruit, mango) that cannot be abstained from during the study period;
  • Special dietary requirements or inability to comply with a standardized diet;
  • Difficulty swallowing tablets;
  • Inability to tolerate venipuncture, history of hemophobia/needle phobia, or poor vascular conditions making blood collection difficult;
  • Use of any drugs that inhibit or induce hepatic drug-metabolizing enzymes within 28 days prior to screening; or use of any prescription drugs, over-the-counter drugs, herbal medicines, or dietary supplements within 2 weeks (or 5 half-lives, whichever is longer) prior to screening;
  • Participation in any clinical trial within 3 months prior to screening; or still within 5 half-lives of an investigational drug from a previous clinical trial at screening;
  • History of blood donation or significant blood loss (≥ 400 mL) within 3 months prior to screening or between screening and first dose; history of blood transfusion within 3 months; or plans to donate blood during the study period;
  • Poor compliance or any other conditions that make the participant unsuitable for the study as judged by the investigator.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo

Matching placebo tablets will be administered orally to participants in the control groups. In the SAD phase (initially planned up to 5 cohorts), a single dose will be given once in the morning under fasting conditions. In the MAD phase (initially planned up to 3 cohorts), placebo will be administered once daily in the morning for 7 consecutive days. The actual number of cohorts may be adjusted based on the safety and tolerability data reviewed by the Safety Review Committee (SRC)

Matching placebo.

Eksperimentell: YY524051 tablets

YY524051 tablets will be administered orally to participants in the treatment groups. In the SAD phase (initially planned up to 5 cohorts), single ascending doses will be given once in the morning under fasting conditions. In the MAD phase (initially planned up to 3 cohorts), multiple ascending doses will be administered once daily in the morning for 7 consecutive days. The actual number of cohorts and dose levels may be adjusted based on the safety and tolerability data reviewed by the Safety Review Committee (SRC).

YY524051 tablets administered orally

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence, severity, and causality of adverse events (AEs) and serious adverse events (SAEs)
Tidsramme: SAD: Day1 to Day 8 MAD: Day1 to Day 14

Safety and Tolerability as assessed by AEs and SAEs

SAD: Day1 to Day 8 MAD: Day1 to Day 14

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Tmax
Tidsramme: Pre-dose to 48 hours post-dose

Peak time: The time required to reach peak concentration after administration

Pre-dose to 48 hours post-dose
Cmax
Tidsramme: Pre-dose to 48 hours post-dose

Peak concentration: The highest blood concentration after administration

Pre-dose to 48 hours post-dose
AUC
Tidsramme: Pre-dose to 48 hours post-dose

Area under the drug time curve: The area surrounded by the blood concentration curve to the time axis.

Pre-dose to 48 hours post-dose
t1/2
Tidsramme: Pre-dose to 48 hours post-dose

Terminal elimination half-life: The time required for the terminal phase blood concentration to decrease by half

Pre-dose to 48 hours post-dose

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

1. desember 2027

Studiet fullført (Antatt)

1. desember 2027

Datoer for studieregistrering

Først innsendt

13. november 2026

Først innsendt som oppfylte QC-kriteriene

13. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • YY524051-I-01
  • CTR20264102 (Annen identifikator: CDE,NMPA)

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere